– CJ Healthcare signed a MOU with Seoul St. Mary’s Hospital on May 22nd for joint research and professional manpower training
– Decided to cooperate in the research for the development of autoimmune disease treatment including rheumatoid arthritis treatment
– Non-clinical research with Joint / Immune Disease Effectiveness Assessment Center in Seoul St. Mary’s Hospital
CJ Healthcare(CEO Kang Seok-Hee) announced on May 23 that it has signed an MOU with The Catholic Univ. of Korea Seoul St. Mary’s Hostpital (hospital director: prof. Seung Gi-Bae) on May 22 for cooperative research on autoimmune diseases such as rheumatoid arthritis.
CJ Healthcare(CEO Kang Seok-Hee) announced on May 23 that it has signed an MOU with The Catholic Univ. of Korea Seoul St. Mary’s Hostpital (hospital director: prof. Seung Gi-Bae) on May 22 for cooperative research on autoimmune diseases such as rheumatoid arthritis.
Through this MOU, the two sides will expand the exchange of research and education personnel and academic information, and plan to increase mutual development and profits by training(또는nurturing) professional manpower and joint research cooperation based on this exchange.
In this agreement ceremony held at Seoul St. Mary’s Hospital, Kang Seok-Hee, CEO of CJ Healthcare, Kim Byeong-Moon, R & D and Business Development Director, Moon Byeong-Seok, the head of research center, Seung Gi-bae, the hospital director, Yang Cheol-Woo, deputy director and Park Sung-Hwan, the director of T2B center and other key partakers attended.
CJ Healthcare plans to conduct non-clinical effectiveness studies with the Joint / Immune Disease Assessment Center in Seoul St. Mary’s Hospital to ensure the competitiveness and differentiation of candidate drugs for autoimmune diseases, including rheumatoid arthritis drugs, which are being developed as new drugs through this agreement .
Under the agreement, CJ Healthcare has drawn up a plan to build competitiveness to secure first-in class drug pipelines by establishing an innovative cluster base through activating industry-university networking.
Currently, most of the market for rheumatoid arthritis drugs, which form the market of about 55 trillion Won (2015, Evaluate pharma) around the world, is dominated by biopharmaceuticals.
CJ Healthcare is also developing a therapeutic drug for rheumatoid arthritis that has improved safety and efficacy, while global pharmaceutical companies are actively conducting research on oral synthetic drugs that have improved the ease of taking medicine.
Kang Seok-Hee, CEO of CJ Healthcare expressed his thoughts: “Through this MOU, CJ Healthcare will be able to share the high-level research and education infrastructure of the Seoul St. Mary’s Hospital.” and “In the future, through non-clinical joint research and collaboration of clinical tests, we look forward to (advancing the time of) accelerating the development of new drugs that can compete globally.”
Seung Gi-Bae, the Seoul St. Mary’s hospital director said, “Based on this agreement with CJ Healthcare, we will do our best to develop a therapeutic agent that will provide a new way to treat arthritis and autoimmune diseases. Through this, we will give hope to a large number of patients in the world suffering from immune diseases.”
